

BIOCON GROUP

FACT SHEET

Dec - 2022

BIOCON LIMITED (CONSOLIDATED)

PROFIT & LOSS STATEMENT

(Rs. Crores)

Particulars	Q3'FY 23	Q3'FY 22	Variance %
INCOME			
Generics	718	607	18%
Biosimilars	1,507	981	54%
Novel Biologics	-	16	-100%
Research services	786	641	23%
Inter-segment	(69)	(72)	-3%
Revenue from operations #	2,941	2,174	35%
Other income	79	48	63%
TOTAL REVENUE	3,020	2,223	36%
EXPENDITURE			
Material & Power costs	1,090	798	37%
Staff costs	520	450	16%
Research & Development expenses*	337	138	144%
Other expenses	349	300	16%
Manufacturing, staff & other expenses	2,297	1,686	36%
EBITDA	723	537	35%
Interest & Finance charges	120	15	718%
Depreciation & Amortisation	301	206	46%
Share of loss / (profit) in JV / Associate, net	56	47	18%
PBT	246	269	-9%
Exceptional item	(271)	-	-
PBT	(25)	269	-109%
Taxes	46	49	-8%
Taxes on exceptional item	(50)	-	0%
NET PROFIT BEFORE MINORITY INTEREST	(21)	220	-109%
Minority interest	60	33	86%
Minority interest on exceptional item	(39)	-	-
NET PROFIT FOR THE PERIOD	(42)	187	-122%
EPS Rs.	(0.3)	1.6	
NET PROFIT BEFORE EXCEPTIONAL ITEM	140	187	-25%
Exceptional item, net of taxes	(182)	-	0%
NET PROFIT FOR THE PERIOD	(42)	187	-122%
# Licensing Income	11	17	
* Gross Research & Development expenses	365	178	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	Q3' FY 23	Q2' FY 23	Variance %
<u>INCOME</u>			
Generics	718	623	15%
Biosimilars	1,507	997	51%
Novel Biologics	-	-	100%
Research services	786	768	2%
Inter-segment	(69)	(69)	1%
Revenue from operations #	2,941	2,320	27%
Other income	79	65	22%
TOTAL REVENUE	3,020	2,384	27%
<u>EXPENDITURE</u>			
Material & Power costs	1,090	850	28%
Staff costs	520	492	6%
Research & Development expenses*	337	242	39%
Other expenses	349	265	32%
Manufacturing, staff & other expenses	2,297	1,849	24%
EBITDA	723	535	35%
Interest & Finance charges	120	30	301%
Depreciation & Amortisation	301	231	30%
Share of loss / (profit) in JV / Associate, net	56	28	96%
PBT BEFORE EXCEPTIONAL ITEM	246	246	0%
Exceptional item, Net	(271)	(17)	-100%
PBT	(25)	229	-111%
Taxes	46	43	7%
Tax expense on adoption of new tax regime - exceptional	-	107	100%
Taxes on exceptional item	(50)	(2)	2087%
NET PROFIT BEFORE MINORITY INTEREST	(21)	82	-125%
Minority interest	60	35	72%
Minority interest on exceptional item	(39)	(0)	-
NET PROFIT FOR THE PERIOD	(42)	47	-189%
EPS Rs.	(0.3)	0.4	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	140	168	-17%
Exceptional item	(182)	(14)	
Tax expense on adoption of new tax regime - exceptional	-	(107)	
NET PROFIT FOR THE PERIOD	(42)	47	-189%
<i># Licensing Income</i>	11	10	
<i>* Gross Research & Development expenses</i>	365	252	

BIOCON LIMITED (CONSOLIDATED)			
PROFIT & LOSS STATEMENT			
(Rs. Crores)			
Particulars	9M' FY 23	9M' FY 22	Variance %
INCOME			
Generics	1,920	1,624	18%
Biosimilars	3,481	2,482	40%
Novel Biologics	-	39	-
Research services	2,199	1,846	19%
Inter-segment	(199)	(215)	-8%
Revenue from operations #	7,400	5,775	28%
Other income	221	145	52%
TOTAL REVENUE	7,621	5,921	29%
EXPENDITURE			
Material & Power costs	2,735	2,124	29%
Staff costs	1,475	1,282	15%
Research & Development expenses*	777	404	92%
Other expenses	898	587	53%
Manufacturing, staff & other expenses	5,886	4,397	34%
EBITDA	1,736	1,524	14%
Interest & Finance charges	171	57	199%
Depreciation & Amortisation	749	602	24%
Share of loss / (profit) in JV / Associate, net	127	154	100%
PBT BEFORE EXCEPTIONAL ITEM	689	711	-3%
Exceptional item, Net	(288)	(70)	311%
PBT	401	641	-37%
Taxes	118	165	-29%
Tax expense on adoption of new tax regime - exceptional	107	-	100%
Taxes on exceptional item	(53)	(12)	-971%
NET PROFIT BEFORE MINORITY INTEREST	229	488	-53%
Minority interest	119	86	38%
Minority interest on exceptional item	(40)	(8)	395%
NET PROFIT FOR THE PERIOD	150	410	-64%
EPS Rs.	1.2	3.4	
NET PROFIT BEFORE EXCEPTIONAL ITEM			
	453	460	-1%
Exceptional item, net of taxes	(196)	(50)	
Tax expense on adoption of new tax regime - exceptional	(107)	-	
NET PROFIT FOR THE PERIOD	150	410	-64%
<i># Licensing Income</i>	31	40	
<i>* Gross Research & Development expenses</i>	839	479	

BIOCON LIMITED (CONSOLIDATED)
BALANCE SHEET

(Rs Crores)

Particulars	December 31, 2022	March 31, 2022
ASSETS		
Non-current assets		
(a) Property, plant and equipment	7,217	5,677
(b) Capital work-in-progress	2,534	3,420
(c) Right-of-use assets	261	267
(d) Goodwill	15,958	26
(e) Other intangible assets	5,831	599
(f) Intangible assets under development	4,654	690
(g) Investment in associates and a joint venture	69	8
(h) Financial assets	-	
Investments	159	362
Derivative assets	160	147
Other financial assets	1,376	45
(i) Income tax asset, net	313	314
(j) Deferred tax asset, net	342	293
(k) Other non-current assets	277	163
Non-current assets	39,151	12,012
Current assets		
(a) Inventories	4,721	2,298
(b) Financial assets		
Investments	1,070	1,218
Trade receivables	4,420	2,058
Cash and cash equivalents	1,057	663
Other bank balances	575	1,085
Derivative assets	67	122
Loans and advances	-	67
Other financial assets	171	451
(c) Other current assets	598	421
(c) Assets held for sale	-	-
Current assets	12,679	8,382
TOTAL - ASSETS	51,830	20,394
EQUITY AND LIABILITIES		
Equity		
(a) Equity share capital	600	600
(b) Other equity	15,096	7,832
Equity attributable to owners of the Company	15,696	8,433
Non-controlling interests	4,173	1,038
Total Equity	19,869	9,470
Non-current liabilities		
(a) Financial liabilities		
Borrowings	14,462	3,999
Lease liabilities	196	222
Derivative liabilities	66	14
Other financial liabilities	4,177	1,503
(b) Provisions	99	92
(c) Deferred tax liability, net	383	52
(d) Other non-current liabilities	1,099	1,215
Non-current liabilities	20,482	7,096
Current liabilities		
(a) Financial liabilities		
Borrowings	5,187	906
Lease liabilities	51	21
Trade payables	4,514	1,609
Derivative liabilities	126	12
Other financial liabilities	501	363
(b) Provisions	155	131
(c) Income tax liability, net	172	162
(d) Other current liabilities	773	625
(e) Liabilities classified as held for sale	-	-
Current liabilities	11,479	3,828
TOTAL - EQUITY AND LIABILITIES	51,830	20,394